利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.023 秒)

    HIV VACCINES COMPRISING ONE OR MORE POPULATION EPISENSUS ANTIGENS
    4.
    发明公开
    HIV VACCINES COMPRISING ONE OR MORE POPULATION EPISENSUS ANTIGENS 审中-公开
    包含一种或更多种群EPISENSUS抗原的HIV疫苗

    公开(公告)号：EP3200878A1

    公开(公告)日：2017-08-09

    申请号：EP15847978.2

    申请日：2015-10-05

    申请人： Los Alamos National Security, LLC ,  Oregon Health & Science University ,  Vir Biotechnology, Inc.

    发明人： BRUENING, Eric ,  FRUEH, Klaus ,  PICKER, Louis ,  KORBER, Bette T.M. ,  THEILER, James ,  MARSHALL, Emily

    IPC分类号： A61P31/18 ,  A61K39/21

    CPC分类号： A61K39/12 ,  A61K39/21 ,  A61K2039/53 ,  A61K2039/70 ,  C12N2710/16143 ,  C12N2740/16034 ,  C12N2740/16234

    摘要： Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.

    摘要翻译： 本文提供了使用EpiGraph方法确定的包含载体和群体遗传抗原的HIV-1疫苗。 还提供了包含载体，群体发生抗原和定制抗原的HIV-1疫苗。 还提供了设计和生产用于受试者的HIV-1疫苗的方法，包括使用EpiGraph方法产生的抗原氨基酸序列设计疫苗抗原以最优地覆盖地理区域内的多样性，并产生所述设计的疫苗抗原。 还提供了诱导效应记忆T细胞应答的方法，包括设计一个或多个EpiGraph氨基酸序列，产生包含一个或多个EpiGraph氨基酸序列的疫苗和载体，并将该疫苗给予受试者。 进一步提供了治疗受试者中的HIV-1的方法，其包括将有效量的所述HIV-1疫苗给予有需要的受试者。

    CYTOMEGALOVIRUS VECTORS ENABLING CONTROL OF T CELL TARGETING
    5.
    发明公开
    CYTOMEGALOVIRUS VECTORS ENABLING CONTROL OF T CELL TARGETING 审中-公开

    公开(公告)号：EP3473723A1

    公开(公告)日：2019-04-24

    申请号：EP18184904.3

    申请日：2014-03-05

    申请人： Oregon Health & Science University

    发明人： PICKER, Louis ,  HANSEN, Scott ,  FRUEH, Klaus ,  MALOULI, Daniel

    IPC分类号： C12N15/86 ,  C12N15/12 ,  A61K48/00 ,  A61P31/06 ,  A61P31/18

    摘要： Disclosed herein are CMV vectors that include a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), an active UL128 protein (or an ortholog thereof), but wherein the CMV vector lacks an active UL130 protein (or an ortholog thereof). Also disclosed herein are CMV vectors comprising: a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), an active UL130 protein (or an ortholog thereof), but wherein the CMV vector lacks an active UL128 protein. Further disclosed are methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II.